Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. (NASDAQ: DARE) is a clinical-stage biopharmaceutical company focused on the advancement of innovative products for women's reproductive health. The company's mission is to identify, develop, and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes, and facilitate convenience for women. Initially, the company's focus is on contraception, vaginal health, and fertility.
Daré's portfolio includes several product candidates in advanced clinical development. Their lead product, Ovaprene, is a non-hormonal monthly contraceptive ring currently undergoing clinical studies. The company's first FDA-approved product, XACIATO (clindamycin phosphate vaginal gel 2%), is a prescription gel for treating bacterial vaginosis in females aged 12 and older. Another prominent product candidate is Sildenafil Cream, 3.6%, a novel formulation intended to treat female sexual arousal disorder (FSAD).
Daré Bioscience has also engaged in significant partnerships to further its mission. For instance, the U.S. commercial rights for Ovaprene are licensed to Bayer, while XACIATO is under a global license agreement with Organon. This collaborative approach has enabled Daré to harness the clinical and market expertise of its partners while retaining control over development and regulatory approval processes.
Recently, Daré has aligned with the FDA on key elements of the Phase 3 program for Sildenafil Cream, setting the stage for a pivotal study to support a New Drug Application (NDA) filing. The company has also received grants, such as the $750,000 from the Bill & Melinda Gates Foundation, to support the development of bacteria-based biotherapeutic products. In addition, Daré is progressing with the clinical development of its hormonal therapy candidate, DARE-HRT1, a bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Daré continues to build on its achievements from 2023, advancing its portfolio of novel investigational therapies, particularly those demonstrating proof of concept. The company actively engages in strategic processes to explore partnering opportunities for additional indications, such as GLP-1s for obesity and metabolic disorders.
Moreover, Daré received a $1 million payment as the latest installment under a grant agreement to advance its investigational contraceptive, DARE-LARC1. This product aims to address specific individual family planning goals with features like precision dosing and wireless control.
For the latest news and updates, investors and interested parties can visit Daré's investor relations website and follow their social media channels. The company remains committed to distributing material information through these channels and encourages stakeholders to stay informed about their developments and milestones.
Daré Bioscience (NASDAQ: DARE) recently announced the advancement of DARE-HRT1 into a single Phase 3 clinical trial to treat vasomotor symptoms (VMS) associated with menopause. The investigational intravaginal ring (IVR) is designed to deliver bio-identical hormone therapy. Topline results from the completed Phase 1/2 trial indicate successful delivery of estradiol and progesterone, with significant improvements in VMS and vaginal symptoms reported. The company plans to file a new drug application under the FDA’s 505(b)(2) pathway, with a focus on FDA approval for moderate to severe VMS in women with intact uteri.
Daré Bioscience (NASDAQ: DARE) announced the development of DARE-PDM1, a new product utilizing hydrogel technology for vaginal delivery of diclofenac to treat primary dysmenorrhea. A Phase 1 study is anticipated in 2023, aiming to fill a void in FDA-approved treatments for this condition. The company reported significant progress in 2022, including a licensing agreement with Organon for XACIATO, and several ongoing clinical trials in innovative women's health programs. The global market for dysmenorrhea treatment is projected to grow from USD 11 billion to USD 25 billion by 2028, indicating strong commercial potential.
Daré Bioscience (NASDAQ: DARE) has secured a grant of $584,986 from the Bill & Melinda Gates Foundation to develop a reconstitutable vaginal thermosetting gel for administering live biotherapeutics. This innovative formulation aims to improve vaginal health and could enhance therapeutic availability, especially in diverse climates. The company is addressing the unmet need for products that restore vaginal microbiota post-infection, with the potential to reduce infection recurrence. Daré's first FDA-approved product, XACIATO, is set for commercial sale in early 2023.
Daré Bioscience, Inc. (NASDAQ: DARE) announced positive topline results from its Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal formulation for treating vulvar and vaginal atrophy (VVA) in postmenopausal women, particularly those with hormone receptor-positive breast cancer. The study demonstrated safety and tolerability, with significant improvements in vaginal cytology and bothersome symptoms. DARE-VVA1 could become the first FDA-approved product for VVA in this patient group, addressing a critical unmet need. The study involved 17 participants, with positive outcomes reported across various doses.
Daré Bioscience reported a strong financial position as of September 30, 2022, with $40.4 million in cash. The company received $18 million in non-dilutive cash, bolstering its balance sheet. Key developments include FDA approval for Ovaprene's pivotal study and positive efficacy data for DARE-HRT1. Additionally, subject screening for Sildenafil Cream's Phase 2b RESPOND study has been completed, targeting topline data announcement in Q2 2023. Daré anticipates the first commercial sale of XACIATO in the U.S. in 1H 2023, aimed at addressing bacterial vaginosis affecting 21 million women.
Daré Bioscience, a leader in women’s health innovation, will have its President and CEO, Sabrina Martucci Johnson, present at the Stifel 2022 Healthcare Conference on November 15, 2022, at 9:10 a.m. ET. The presentation will be available via live webcast on the company's website and archived until November 29, 2022. Daré is committed to advancing innovative therapies for women’s health, including FDA-approved products like XACIATO and candidates such as Ovaprene and Sildenafil Cream. For more details, visit their investor relations page.
Daré Bioscience (NASDAQ: DARE) will host a conference call on November 10, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and provide company updates. Interested participants can access the call by dialing (800) 715-9871 for U.S. callers or (646) 307-1963 internationally. The call will also be available via a live webcast on Daré's Investor Relations website. The company focuses on women's health innovations, including its first FDA-approved product, XACIATO, for bacterial vaginosis, and several candidates in clinical development.
Daré Bioscience (NASDAQ:DARE) has completed subject screening for its Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, a potential treatment for female sexual arousal disorder (FSAD). Approximately 100 out of the expected 160-170 subjects have completed study assessments to date. Topline data is anticipated by 2Q-2023. This study represents a significant milestone as there are currently no FDA-approved therapies for FSAD, and Sildenafil Cream aims to be the first approved treatment for this condition.
Daré Bioscience announced positive topline results from its Phase 1/2 clinical trial of DARE-HRT1, an investigational intravaginal ring designed to deliver continuous hormone therapy for menopausal symptoms. DARE-HRT1 showed statistically significant improvements in vasomotor symptoms and vaginal conditions associated with menopause, with 100% of participants finding it comfortable to use. The innovative IVR technology allows consistent drug release without a membrane. Daré plans to leverage this data for FDA approval through the 505(b)(2) pathway.
Daré Bioscience (NASDAQ: DARE) has received FDA approval for an Investigational Device Exemption (IDE) to initiate a pivotal study for Ovaprene, a hormone-free monthly contraceptive. The single-arm study will assess Ovaprene's efficacy, safety, and usability. Previous trials indicated Ovaprene effectively blocked sperm entry. The FDA's approval validates the company's data and aligns on study duration and design. If successful, this could lead to marketing approval for what may become the first FDA-approved monthly self-administered contraceptive. Study recruitment is targeted for mid-2023.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
What is Daré Bioscience's main focus?
What is Ovaprene?
Who are Daré Bioscience's key partners?
What is Sildenafil Cream, 3.6% used for?
What is XACIATO?
What are some recent achievements of Daré Bioscience?
What grant support has Daré Bioscience received?
What is DARE-LARC1?
How does Daré Bioscience distribute material information?